NCT02447328 - A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 29, 2015

Primary Completion Date

May 6, 2016

Study Completion Date

September 16, 2020

Conditions

Locally Advanced orMetastatic Breast Cancer

Interventions

DRUG

Fulvestrant

fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.

Trial Locations (9)

Research Site, Goyang-si

Research Site, Seongnam-si

Research Site, Cheongju-si

Research Site, Daegu

Research Site, Seogu

Research Site, Seoul

Research Site, Seoul

Research Site, Seoul

Research Site, Seoul